Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2017-04-05 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于对公司控股股东及其他关联方占用资金情况的专项审计说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计说明" which translates to "Special Audit Explanation" for the year 2016. It specifically addresses the audit of the company's controlling shareholders and related parties' fund occupation situation. The text includes references to audit responsibilities, standards, and an audit opinion on a specific financial summary table related to related-party fund usage. It is issued by a registered accounting firm and signed by certified public accountants. The document is not a full annual report or interim report but a standalone audit report focusing on a specific audit area (related-party fund occupation). The length is under 5,000 characters and contains detailed audit opinion and financial data related to the audit scope. This fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. Therefore, the correct classification is AR with high confidence. FY 2016
2017-04-05 Chinese
2016年年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (334 characters) from the company's board stating that the full 2016 Annual Report has been published on an official disclosure website. It does not contain the actual report or financial data but directs investors to where the report can be found. This fits the pattern of a Report Publication Announcement (RPA) rather than the Annual Report (10-K) itself.
2017-04-05 Chinese
关于和Xcovery公司就全球多中心Ⅲ期临床试验（中国区）合作暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a cooperation agreement and related party transaction between the company and Xcovery Holding Company LLC for a global multi-center Phase III clinical trial in China. It details the transaction amount, board approvals, related party disclosures, and independent director opinions. There are no financial statements or detailed financial performance data presented. The document is a formal announcement of a corporate transaction and related party cooperation, not a financial report or earnings release. It fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement about a related party transaction and cooperation agreement without substantive financial data or report content.
2017-03-27 Chinese
第二届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the sixth meeting of the second Supervisory Board of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, agenda, and voting results regarding a cooperation agreement for a clinical trial project. The content focuses on board-level decision-making and meeting resolutions rather than financial results, audit opinions, or regulatory filings. It does not contain financial statements or earnings data, nor is it a report or presentation. The document is an official announcement of a board/management decision, specifically related to the Supervisory Board's meeting resolution. Therefore, it fits best under 'Board/Management Information (MANG)'. The document length is short and it is not a report publication announcement or certification. Confidence is high due to clear meeting and resolution content.
2017-03-27 Chinese
关于为全资子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 贝达药业股份有限公司 regarding the provision of a guarantee for its wholly-owned subsidiary 贝达投资（香港）有限公司. It details the board meeting resolution approving the guarantee, the guarantee amount, the subsidiary's financial status, and opinions from the board and independent directors. The document is focused on a specific corporate action related to financing support for a subsidiary, not a full financial report or earnings release. It is not an annual or interim report, audit report, or earnings release. It is also not a regulatory filing or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it concerns the company's financing activities and guarantees provided to a subsidiary for bank credit.
2017-03-27 Chinese
第二届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 9th meeting of the 2nd Board of Directors of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and voting results on specific proposals such as guarantees for a subsidiary and cooperation agreements. There is no financial data or report content, only the board meeting decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (2024 characters) and it is not an announcement of a report publication but a meeting resolution announcement. Therefore, the correct classification is MANG with high confidence.
2017-03-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.